These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7924892)

  • 21. [Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
    Castillo JL; Miranda CM; Araya F; Sáez D
    Rev Med Chil; 1996 Mar; 124(3):301-6. PubMed ID: 9008941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The abnormality of N30 somatosensory evoked potential in idiopathic Parkinson's disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations.
    Onofrj M; Fulgente T; Malatesta G; Ferracci F; Thomas A; Curatola L; Bollettini F; Ragno M
    Mov Disord; 1995 Jan; 10(1):71-80. PubMed ID: 7885358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Yamaguchi M; Mizuta E; Kuno S
    Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model.
    Ghilardi MF; Bodis-Wollner I; Onofrj MC; Marx MS; Glover AA
    Brain; 1988 Feb; 111 ( Pt 1)():131-49. PubMed ID: 3259150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M; Madras BK
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
    Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences between primary somatosensory cortex- and vertex-derived somatosensory-evoked potentials in the rat.
    Stienen PJ; van den Brom WE; de Groot HN; Venker-van Haagen AJ; Hellebrekers LJ
    Brain Res; 2004 Dec; 1030(2):256-66. PubMed ID: 15571674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lesions in monkey globus pallidus externus exacerbate parkinsonian symptoms.
    Zhang J; Russo GS; Mewes K; Rye DB; Vitek JL
    Exp Neurol; 2006 Jun; 199(2):446-53. PubMed ID: 16487515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes.
    Pierantozzi M; Sabato AF; Leonardis F; Marciani MG; Cicardi C; Giacomini P; Bernardi G; Stanzione P
    Exp Brain Res; 2000 Aug; 133(3):368-76. PubMed ID: 10958527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Median nerve somatosensory evoked potentials. Apomorphine-induced transient potentiation of frontal components in Parkinson's disease and in parkinsonism.
    Rossini PM; Bassetti MA; Pasqualetti P
    Electroencephalogr Clin Neurophysiol; 1995 May; 96(3):236-47. PubMed ID: 7750449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?
    Luquin MR; Saldise L; Guillén J; Belzunegui S; San Sebastián W; Izal A; Garrido P; Vázquez M
    Exp Neurol; 2006 Oct; 201(2):407-15. PubMed ID: 16806173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.